Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Koygo Co., Ltd.

Fumio Suzuki

Junichi Shimada

Kenji Ohmori

Akio Ishii

Hiromi Nonaka

Takeshi Kuroda

Shunji Ichikawa

Shigeto Kitamura

Kazuhiro Kubo

Shizuo Shiozaki

Akira Karasawa

Yoshisuke Nakasato

Haruhiko Manabe

Joji Nakamura

Nobuaki Koike

Tetsuji Ohno

Hiroaki Hayashi

Soichiro Sato

Tadafumi Tamura

Yoshikazu Miwa

Michio Ichimura

Hiroshi Nakajima

Takashi Kawakita

Hiroshi Tsumuki

Hiroshi Kase

Yoshihisa Kuwana

Ichiro Miki

Etsuo Ohshima

Katsuichi Shuto

Hideaki Kusaka

Tomoyuki Kanda

Nobuo Kosaka

Kyoichiro Iida

Hidee Ishii

Koji Yanagawa

Junichi Ikeda

Tohru Matsuzaki

Tohru Yasuzawa

Masako Kurokawa

Ken Ikeda

Hisashi Hosoe

Rie Koike

Hiroshi Tanaka

Tatsuya Tamaoki

Toshikazu Kamiya

Kenichi Mochida

Takashi Kuwabara

Tamotsu Eguchi

Hiromasa Kato

Mayumi Saki

Hironori Imma

Akiko Nakamura

Akira Horiguchi

Yoshisuke Nakazato

Kazuihiro Kubo

Ikufumi Yoshitake

Hideaki Mizumoto

Hiroshi Magara

Shizuo Shioazaki

The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.

Method of treating brain ischemia

Remedial agent for neural degeneration

Derivatives of benzofuran or benzodioxazole compounds

Derivatives of benzofuran or benzodioxole

The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A,acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I):

Condensed purine derivatives

&lsqb;1,2,4&rsqb;Triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A,receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A,receptors (for example, Parkinson's disease or senile dementia):

&lsqb;1,2,4&rsqb; triazolo &lsqb;1,5-C&rsqb; pyrimidine derivatives

Process for producing xanthine derivatives with bacteria and fungi

Method of treating depression with certain triazine derivatives

The present invention relates to novel xanthine derivatives of the formula (I) which are selectively antagonistic to an adenosine A.sub.2 receptor, and pharmaceutically acceptable salts thereof. Formula (I): ##STR1## In the formula, R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a propyl group, a butyl group or an allyl group; R.sup.3 represents a hydrogen atom or a lower alkyl group; Y.sup.1 and Y.sup.2 are the same or different and each represents a hydrogen atom or a methyl group; and Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a thienyl group.

Xanthine derivatives

Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl;

8-substituted styryl xanthine derivatives

Tetracyclic compound

Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.

Therapeutic agent for Parkinson's disease

Therapeutic purine agents for parkinson's disease

Antidepressants

Growing community of inventors

Mishima, Japan

Fumio Suzuki